Compare Incyte Corporation (INCY) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs TJX Companies Inc — how do they compare? Incyte Corporation trades at $118.01 (market cap $23.11B), while TJX Companies Inc trades at $154.24 (market cap $172.00B). The key difference: TJX Companies Inc is far larger — about 7.4× Incyte Corporation's market cap, and TJX Companies Inc pays a 1.23% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TJX | |
|---|---|---|
Market Cap | $23.11B | $172.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $168.41 |
52-Week Low | $67.38 | $124.53 |
Enterprise Value | $19.13B | $180.60B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
TJX trades at $155.47, up 0.7% on the day, with a bullish technical signal and strong fundamental performance. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate. Revenue growth is robust, reaching $56.36 billion in 2025, with a net income margin of 9.4%. Analyst sentiment is overwhelmingly positive, with 88% recommending Buy and a consensus price target of $181.80, suggesting significant upside potential from current levels.
The outlook for TJX remains favorable, driven by sustained earnings beats, expanding margins, and strategic international growth. Key risks include competitive pressures in discount retail and sensitivity to consumer spending trends. With strong cash flow generation supporting dividends and buybacks, TJX presents a compelling growth story, though valuation metrics like a P/E of 30.05 warrant monitoring for overextension.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
